Breast Cancer Research Program
Breast cancer is the second most common cancer in women after skin cancer. Only 5 –10% of breast cancers are estimated to be due to genetic predisposition. Several hormonal factors are associated with the higher risk of breast cancer. These include early age at menarche and late menopause, nulliparity, or the first pregnancy after 30 years of age, and long-term hormone replacement therapy. “Phytogen”, Phyto-estrogens are plant compounds structurally similar to endogenous estrogens, which have been proposed have protective effects against breast cancer.
Renu Bio Health conducts clinical trials to test potential breast cancer treatments in human volunteers to see whether they should be approved for wider use in the general population.